8 withdrawn. 8 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 8 | Withdrawn 8 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Augmented Macular Pigment-containing Nutraceutical and Central Visual Function Lumega-Z, Dorzolamide Hcl 2% Oph Soln, Placebo - Glaucoma, Glaucoma Eye | Phase 4 | Withdrawn | University of the Incarnate Word | 2021-05-01 | 2022-10-04 | |
| African Glaucoma Laser Trial Selective laser trabeculoplasty (SLT), Latanoprost ophthalmic solution, Timolol ophthalmic solution - Open-angle Glaucoma | Phase 4 | Withdrawn | West Virginia University | 2019-09-01 | 2021-06-21 | |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav) - Glaucoma, Ocular Hypertension | Phase 4 | Withdrawn | Alcon Research | 2013-02-01 | 2013-02-07 | |
| The Laser in Pseudoexfoliation (LIP) Study SLT Laser, Prostagladin - Glaucoma | Phase 4 | Withdrawn | Nova Scotia Health Authority | 2012-06-01 | 2024-08-21 | |
| Travacom Post Marketing Surveillance Study Travoprost/timolol fixed combination (Travacom) - Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Withdrawn | Alcon Research | 2012-01-01 | 2012-10-18 | |
| Effect of Rosuvastatin on Endothelial Function in Patients With Diabetes and Glaucoma Rosuvastatin, Placebo - Glaucoma, Diabetes | Phase 4 | Withdrawn | Medical University of Vienna | 2009-06-01 | 2014-11-21 | |
| Use of Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery Bevacizumab - Glaucoma | Phase 4 | Withdrawn | Nova Scotia Health Authority | 2008-07-01 | 2024-08-21 |
Glaucoma, Open-Angle (3) · Ocular Hypertension (3) · Diabetes Mellitus (1) · Graves Disease (1) · Graves Ophthalmopathy (1)
Eye Diseases (8) · Ocular Hypertension (5) · Endocrine System Diseases (2) · Autoimmune Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Exophthalmos (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Goiter (1) · Hyperthyroidism (1) · Immune System Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Travoprost (3) · Timolol (2) · Bevacizumab (1) · Bimatoprost (1) · Duotrav (1) · Latanoprost (1) · Prostaglandins, Synthetic (1) · Rosuvastatin Calcium (1) · brinzolamide (1) · dorzolamide (1) · tafluprost (1)
Alcon Research (2) · Nova Scotia Health Authority (2) · Medical University of Vienna (1) · Stanford University (1) · University of the Incarnate Word (1) · West Virginia University (1)
Canada (2) · United States (2) · Austria (1)
Abayomi Ogundele, PharmD (1) · Andrea L. Kossler, M.D. (1) · Anthony D Realini, MD (1) · Gerhard Garhofer, MD (1) · Grant T Slagle, DO (1) · Lesya Shuba, MD PhD (1) · Marcelo T Nicoela, MD (1)